DSY Dassault Systemes SA

Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of September 30, 2025

Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of September 30, 2025

Press Release

VELIZY-VILLACOUBLAY, France — October 7, 2025

                

Declaration of the number of outstanding shares and

voting rights as of September 30, 2025

(Euronext Paris: FR0014003TT8, DSY.PA) today announced below the total number of its outstanding shares and voting rights as of September 30, 2025, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers.

Number of outstanding shares: 1,341,653,585

Number of voting rights*: 2,013,496,529

*The total number of voting rights is calculated on the basis of the total number of outstanding shares, even if the voting rights attached thereto are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers relating to the method for calculating the percentages of holdings in shares and in voting rights. We invite our shareholders to refer to this article should they need to declare crossing of thresholds.

Declarations related to crossing of threshold must be sent to:

Dassault Systèmes, Investor Relations Service, 10, rue Marcel Dassault, CS 40501, 78946 Vélizy-Villacoublay Cedex (France). E-mail address:   

###

ABOUT DASSAULT SYSTÈMES

Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes’ 3DEXPERIENCE platform, 370 000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit

Dassault Systèmes Investor Relations Team                FTI Consulting

Béatrix Martinez :                                        Arnaud de Cheffontaines: 48

73                                        Jamie Ricketts : 0

                                        

Dassault Systèmes Press Contacts

Corporate / France        

Arnaud Malherbe / Déborah Cobbi

73 / 83

 /

Attachment



EN
07/10/2025

Underlying

DSYDassault Systemes SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dassault Systemes SA

 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

4h / 42m 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec...

Mise à jour : Dassault Systèmes : Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Medidata étend sa collaboration avec Sanofi pour développer de nouvelles thérapies visant à améliorer le parcours patient Une collaboration de plus de dix ans renforcée autour des Medidata Experiences, a pour l’objectif d’optimiser les processus et les données cliniques en améliorant la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des solutions numériques pour les essais cliniques...

4h / 42m 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi ...

Update: Dassault Systèmes: Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey  Expanded 10-plus-year collaboration will leverage Medidata Experiences with the goal of streamlining clinical processes and data, enhancing patient care New York – Oct. 23, 2025 –, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced an extension of their collaboration w...

8h / 49m 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration ave...

Mise à jour : Dassault Systèmes : Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Sanofi renforce sa collaboration avec Medidata pour accélérer le développement de nouvelles thérapies et améliorer le parcours patient Une collaboration de plus de dix ans élargie autour des Medidata Experiences, permettant à Sanofi d’optimiser ses opérations, d’affiner la qualité de ses données et d’améliorer la prise en charge des patients. New York, le 23 octobre 2025 – , marque de Dassault Systèmes et leader des soluti...

8h / 49m 1 EN
 PRESS RELEASE
Free
DSY Dassault System...

Dassault Systèmes: Solid third quarter with strong operational perform...

Dassault Systèmes: Solid third quarter with strong operational performance: Confirming full-year EPS growth on adjusted revenue outlook Press Release VELIZY-VILLACOUBLAY, France — October 23, 2025 Dassault Systèmes: Solid third quarter with strong operational performance Confirming full-year EPS growth on adjusted revenue outlook (Euronext Paris: FR0014003TT8, DSY.PA) today reports its IFRS unaudited estimated financial results for the third quarter 2025 and nine months ended September 30, 2025. The Group’s Board of Directors approved these estimated results on October 22, 2025. This p...

October 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch